Number of the records: 1
Molecular targets on mast cells and basophils for novel therapies
- 1.
SYSNO ASEP 0435403 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Molecular targets on mast cells and basophils for novel therapies Author(s) Harvima, I.T. (FI)
Levi-Schaffer, F. (IL)
Dráber, Petr (UMG-J) RID
Friedman, S. (IL)
Polakovičová, Iva (UMG-J)
Gibbs, B.F. (GB)
Blank, U. (FR)
Nilsson, G. (SE)
Maurer, M. (DE)Source Title Journal of Allergy and Clinical Immunology. - : Elsevier - ISSN 0091-6749
Roč. 134, č. 3 (2014), s. 530-544Number of pages 15 s. Language eng - English Country US - United States Keywords cell activation ; mast cells and basophils ; treatment of allergic diseases Subject RIV EB - Genetics ; Molecular Biology R&D Projects LD12073 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) GBP302/12/G101 GA ČR - Czech Science Foundation (CSF) GA14-09807S GA ČR - Czech Science Foundation (CSF) GA14-00703S GA ČR - Czech Science Foundation (CSF) Institutional support UMG-J - RVO:68378050 UT WOS 000341372400004 DOI 10.1016/j.jaci.2014.03.007 Annotation Mast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D-2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, Fc gamma RIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2015
Number of the records: 1